MapLight Therapeutics, Inc. (MPLT)
7.97
-0.28
(-3.39%)
USD |
NASDAQ |
Oct 23, 16:00
7.97
0.00 (0.00%)
After-Hours: 20:00
MapLight Therapeutics Enterprise Value : 59.39M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 59.39M |
| October 22, 2026 | 72.12M |
| October 21, 2026 | 68.03M |
| October 20, 2026 | 71.66M |
| October 19, 2026 | 60.76M |
| October 16, 2026 | 47.13M |
| October 15, 2026 | 61.67M |
| October 14, 2026 | 52.12M |
| October 13, 2026 | 55.08M |
| October 12, 2026 | 88.02M |
| October 09, 2026 | 98.47M |
| October 08, 2026 | 113.01M |
| October 07, 2026 | 122.55M |
| October 06, 2026 | 137.55M |
| October 05, 2026 | 118.69M |
| October 02, 2026 | 143.45M |
| October 01, 2026 | 134.82M |
| September 30, 2026 | 160.26M |
| September 29, 2026 | 158.45M |
| September 28, 2026 | 172.08M |
| September 25, 2026 | 172.53M |
| September 24, 2026 | 186.16M |
| September 23, 2026 | 186.62M |
| September 22, 2026 | 190.71M |
| September 21, 2026 | 192.52M |
| Date | Value |
|---|---|
| September 18, 2026 | 193.43M |
| September 17, 2026 | 211.61M |
| September 16, 2026 | 215.24M |
| September 15, 2026 | 246.14M |
| September 14, 2026 | 294.76M |
| September 11, 2026 | 287.94M |
| September 10, 2026 | 323.61M |
| September 09, 2026 | 320.20M |
| September 08, 2026 | 331.11M |
| September 04, 2026 | 322.93M |
| September 03, 2026 | 294.30M |
| September 02, 2026 | 290.67M |
| September 01, 2026 | 302.03M |
| August 31, 2026 | 286.58M |
| August 28, 2026 | 269.77M |
| August 27, 2026 | 267.04M |
| August 26, 2026 | 281.58M |
| August 25, 2026 | 267.04M |
| August 24, 2026 | 213.43M |
| August 21, 2026 | 206.61M |
| August 20, 2026 | 207.52M |
| August 19, 2026 | 249.32M |
| August 18, 2026 | 234.33M |
| August 17, 2026 | 208.20M |
| August 14, 2026 | 231.15M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Cullinan Therapeutics, Inc. | 595.12M |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -60.19M |
| Total Expenses (Quarterly) | 60.19M |
| EPS Diluted (Quarterly) | -1.325 |
| Earnings Yield | -64.27% |
| Normalized Earnings Yield | -64.27 |